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ABSTRACT
This report aims to inform on the progression of research into the genetic factors involved in the development of 
Alzheimer’s disease (AD). AD is a life-altering disease that affects millions of individuals from varying races and 
ethnic backgrounds1. According to the National Institute on Aging, a faculty of the U.S. Department of Health and 
Human Services, AD has been ranked as the third leading cause of death in the United States, only behind cancer 
and heart failure. It is predicted that by 2050, approximately one in 45 Americans will be afflicted with the disease5. 
Distinctive physical indications of the onset of AD include neuron loss, amyloid plaques and neurofibrillary 
tangles5. Onset is not frequent prior to 60 years of age but can be caused by one of two reasons. The first is 
a mutation in the amyloid precursor protein (APP) gene on chromosome 21. This gene is responsible for the 
regulation of the production of amyloid beta (Aβ) proteins, which are known to be abundant in the brains of 
AD patients. A mutation in the gene leads to an inappropriate regulation of this protein. The second, and more 
common cause is a result of an unidentified gene on chromosome 14 in AD patients2. It has been confirmed that 
there is involvement of chromosome 19 in late onset AD (LOAD)  as well1. Most of the genes that are associated 
with the development of AD have yet to be identified, but the research is bringing society closer and closer to 
that goal everyday.
Ce rapport vise à fournir de l’information sur la progression de la recherche au sujet des facteurs génétiques 
impliqués dans le développement de la maladie d’Alzheimer (MA). La MA est une maladie bouleversant la vie 
de la personne et qui affecte des millions d’individus de diverses races et ethnicité1. Selon l’Institut national sur le 
vieillissement, un corps professoral du département américain de la santé et des services sociaux, la MA a été 
classée comme la troisième cause de décès aux États-Unis, ne cédant le pas qu’au cancer et à l’insuffisan e 
cardiaque. Il est prévu que d’ici l’an 2050, environ une personne sur 45 Américains sera affligée avec cette maladie5.
Des indications visuelles distinctives de l’apparition de la MA comprennent la perte des neurones, les plaques 
amyloïdes et des enchevêtrements neurofibrillaire 5. L’apparition précoce n’est pas fréquente avant 60 ans, 
mais peut être causée par l’une des deux raisons. La première raison est une mutation dans le gène de la 
protéine précurseur de l’amyloïde (PPA) sur le chromosome 21. Ce gène est responsable de la régulation 
de la production de protéines bêta-amyloïde (Aß), qui sont connues pour être abondant dans le cerveau des 
patients atteints de la MA. Une mutation dans le gène conduit à une régulation inappropriée de cette protéine. 
La seconde cause, et celle-là plus communes sont le résultat d’un gène inconnu sur le chromosome 142. Il a 
été confirmé qu’il y a aussi une participation du chromosome 19 dans l’apparition tardive de la MA (ATMA)1. La 
plupart des gènes qui sont associés avec le développement de la MA n’ont pas encore été identifiés, mais la 
recherche rapproche la société de cet objectif de plus en plus tous les jours.
INTRODUCTION
Article 1: Gene Dose of Apoliprotein E Type 4 
Allele and the Risk of Alzheimer’s disease in 
Late Onset Families1
In a seminal paper in the field of AD genetics, 
Corder et al.1, aimed to show that the APOE4 gene 
expression is related to an elevated risk as well as 
an earlier onset period of AD. The late onset variation 
of AD has been associated with the APOE4 allele on 
chromosome 191. The first aspect of this study aimed 
to determine whether or not the aforementioned allele 
was in fact responsible for early onset AD. This was 
found to be the case.1 Approximately 64% of AD late 
onset cases have at least one APOE4 allele.1 
The researchers subsequently studied the presence 
of this allele, and how expression affected the age 
of onset. It was found that each additional APOE4 
allele constituted a younger onset age. From no 
APOE4 allele to only one, the drop in age was far 
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the  drop  in  age  was  far  more drastic than  that  
of the difference between subjects  with  one  
APOE4 allele and two.
The allelic association found can be attributed to 
genetic linkage disequilibrium; two loci (chromosome  
locations) are situated close enough to each other 
that recombination is rare1. As a result, these alleles 
can be passed through many generations in their 
original orientation.1 It was reported that there is a 
genetic linkage between late onset AD and the loci 
residing near APOE.1 It is important to recognize  
that while the presence and dosage of the APOE4  
allele plays a role in determining age of onset for 
AD patients, it is not the determining factor for 
whether a person will develop the disease or not. 
$UWLFOH,QWHJUDWLYH*HQRPLFV,GHQWLILHV$32( 
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The study by Rhinn et al.2, written a decade after 
the Corder et al.1 study describes in more 
detail the  procedures  used  to  determine  that  the  
APOE4 allele is associated with LOAD. In order to 
determine the pathways that result in LOAD in 
an unbiased fashion, differential co-expression 
analysis (DCA) was used. This method aims to 
differentiate between causative events (i.e. the 
events that cause the LOAD) and secondary 
changes, which are in fact a result of the 
causative events but appear to be the causative 
events. DCA can be used to identify regulatory 
mechanisms that affect LOAD and those that 
affect LOAD risk2. Through this method, two  key  
points  were  determined.  The  first  was  the  
identification of APBA2, ITM2B, FYN, RNF219, and  
SV2A as genes, that mediate the transcriptomic 
changes  observed  in  APOE4  carriers  as  well  as  
LOAD patients. Secondly, genome-wide association 
study  (GWAS)  data  showed  that  common  genetic  
variants  within  two  of  the  mentioned  genes,  FYN  
and  RNF219,  are  associated  with  LOAD.  In  order  
to determine whether the DCA node genes (above) 
function as regulators of amyloid precursor protein 
(APP), mouse neuroblastoma cells with human APP 
transgene were injected with APOE protein 
variants. Treatments  with  human  APOE4  (not  
APOE2  or  APOE3) increased  the  levels of Aβ  
plaque present, build-up of which predicts AD. 
Next, this study hypothesized that a SV2A inhibitor 
called levetiracetam (used to treat seizure 
disorders) could also be used to correct APOE4 
related alteration in APP processing. It was found 
that levetiracetam drastically decreased excess Aβ 
levels. This determined that SV2a is necessary for 
the APOE4-facilitated induction of APP processing. 
Since it was determined that DCA genes function as 
regulators for APP, it is sound to suggest that variants 
at these gene loci may control the association of 
APOE4 with LOAD (i.e. risk or age-of-onset)2.
In conclusion, it was established that APOE4 is 
linked to heightened Aβ brain accumulation, which 
in turn results in accelerated cognitive deterioration. 
However, since not all APOE4 carriers develop LOAD, 
it is apparent that there are other factors involved 
in its development. Additionally, levetiracetam was 
demonstrated to rekindle cognition in individuals 
with mild cognitive deﬁciency2. When tested in mice 
however, in the absence of human APOE4, the 




In previous reports, AD risk pathways were 
investigated by analyzing individual GWAS datasets 
in isolation. In this study, Liu et al. propose that 
multiple GWAS be investigated simultaneously in 
order to identify new AD risk pathways. 
In the analysis, Liu et al.3 replicated previous GWAS 
ﬁndings, including AD risk genes such as TOMM40, 
PVRL2, APOE, CLU, CR1, PICALM, MS4A6A, 
MS4A2, ABCA7, and EXOC3L2. Furthermore, 
novel AD susceptibility genes were identiﬁed with 
the most signiﬁcant belonging to the APOE family 
of genes. The latter was to be expected since as 
discussed in the previous articles, the APOE gene 
has been found to be the most prevalent risk factor 
for LOAD. Previous studies have shown that there is 
an involvement of pathways related to metabolism, 
the immune system, signaling molecules and 
interaction, and neurodegenerative diseases in AD 
risk. There are four signiﬁcant pathways linked to 
cardiovascular disease (CVD), three of which are 
also linked to AD. Although not certain, this study 
suggests that the associations between CVD and 
AD pathways are related to shared genetic factors.
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Lambert et al.4 describe the largest meta-analysis 
(combining datasets from previous GWAS) that 
currently exists of genetic factors associated with AD 
risk. The authors successfully determined 11 new 
possible loci that play a role in AD risk. Previously, 
there were nine identiﬁed loci associated with late-
onset AD. The search for additional loci however, 
requires a larger sample size in order for meta-
analyses to be conducted with apt statistical power.
In this study, the ﬁrst stage of meta-analysis was 
completed using four conglomerates, with quality 
control being conducted for the genetic variants. 
Those that did not pass the control were excluded 
from the analysis. 
As aforementioned, the APOE locus is a critical region 
in predicted LOAD. In addition to this locus, 14 other 
regions had signiﬁcant associations. Nine of these 
were previously identiﬁed as susceptibility factors, 
but ﬁve are representative of newly discovered 
associated loci. An example is SORLI. Of these newly 
associated loci, it is apparent that these may or may 
not be causative genes. In addition to the already 
identiﬁed genes, the most signiﬁcant new association 
is the HLA-DRB5-DRB1 region. Interestingly, this 
is a region commonly associated with two other 
neurodegenerative disorders; multiple sclerosis and 
Parkinson’s disease. The study was inconclusive on 
which gene(s) were responsible for the signal from this 
region. The second strongest signal was associated 
with the SORLI gene, a critical region related to an 
increased risk of autosomal dominant and sporadic 
forms of AD4. The third and fourth most signiﬁcant 
loci identiﬁed are PTK2B and SLC25A4, respectively. 
The latter of the two is commonly involved in iris, 
hair, and skin colour variation in humans as well 
as neural development. Another signiﬁcant locus 
that was identiﬁed was near MEF2C. Mutations 
here commonly result in severe mental deﬁciency, 
epilepsy, and cerebral malformation. 
This study is a clear example of the ever-developing 
research behind AD–oriented genetics. The fact that 
through this one study 11 additional potential loci 
associated with the development of AD have been 
identiﬁed exempliﬁes the accelerating world of research, 
and moves us closer and closer towards understanding 
the genetic factors contributing to AD risk.
CONCLUSION
As humans, we strive to have a clear understanding 
of everything we encounter. We are passionately 
curious by nature – an excellent quality since it has 
enabled our lives to advance farther than any other 
species. Our lives consist of a string of experiences, 
which aid us in living the remainder of our lives. The 
past guides the present. What happens, though, 
when there is no past? What happens when there is 
no recollection of what you ate for dinner yesterday, 
or what you had for breakfast this morning? Life is 
no longer simple at that point. This uncertainty is the 
reality of individuals living with AD. The key to making 
the lives of those afﬂicted easier, is understanding 
what lies beneath the symptoms. This knowledge 
comes from ongoing research. 
This paper outlined four independently completed 
research papers, each assessing various loci that 
are potentially responsible for the development 
of AD. Conclusively, it is apparent that the single 
most important region identiﬁed is APOE41-4. The 
mutation at this location is present in all patients 
with LOAD. However, it is also known that not 
all individuals who have a mutation within this 
locus develop AD. This incomplete penetrance is 
indicative of the fact that there is more than one 
cause for this disease. As of 2013, at least 25 critical 
loci have been identiﬁed that contribute to AD risk. 
By identifying the genetic origins of the disease, 
prevention can become a reality. The medical world 
is developing into one of preventative medicine 
rather than curative. This transition is only possible 
if we have a clear understanding of what it is we are 
trying to prevent, and how to speciﬁcally go about it. 
The aforementioned research projects, and the likes 
of them, move us closer to our goal of being able to 
detect and prevent AD.
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